DDInter893 DDInter1658
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Hydroxychloroquine {u} (Compound) resembles {v} (Compound) Chloroquine
Hydroxychloroquine {u} (Compound) resembles {v} (Compound) Amodiaquine
Hydroxychloroquine {u} may lead to a major life threatening interaction when taken with {v} Primaquine
Hydroxychloroquine {u} (Compound) binds {v} (Gene) TLR9
Hydroxychloroquine {u} (Compound) upregulates {v} (Gene) PAK1
Hydroxychloroquine {u} (Compound) downregulates {v} (Gene) TES
Hydroxychloroquine {u} (Compound) causes {v} (Side Effect) Vomiting
Hydroxychloroquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Hydroxychloroquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Hydroxychloroquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iodide I-131
Hydroxychloroquine (Compound) resembles Chloroquine (Compound)
Hydroxychloroquine (Compound) resembles Amodiaquine (Compound)
Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Hydroxychloroquine (Compound) binds TLR9 (Gene)
Hydroxychloroquine (Compound) upregulates PAK1 (Gene)
Hydroxychloroquine (Compound) downregulates TES (Gene)
Hydroxychloroquine (Compound) causes Vomiting (Side Effect)
Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131